Second malignancies after a gastrectomy for gastric cancers: The effects of adjuvant therapies

Anticancer Research

Volumn 19, Issue 4 C, 1999, Pages 3591-3599

  Nio, Yoshinori ^a   Hirahara, Noriyuki ^a   Minari, Yoshimitsu ^a   Sasaki, Susumu ^a   Takamura, Michio ^a   Sato, Yoshitoshi ^a   Inoue, Yasushi ^a   Nagami, Haruhiko ^a   Tamura, Katsuhiro ^a  

^a SHIMANE UNIVERSITY   (Japan)

Author keywords

Adjuvant therapy; Chemotherapy; Gastrectomy; Gastric cancer; Immunotherapy; Second malignancy

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROPYRIMIDINE; IMMUNOMODULATING AGENT;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CANCER; DISEASE COURSE; DRUG EFFICACY; FEMALE; FOLLOW UP; GASTRECTOMY; HEAD AND NECK CANCER; HUMAN; INCIDENCE; INTRAVENOUS DRUG ADMINISTRATION; LIVER CANCER; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SECOND CANCER; STOMACH CANCER;

ADULT; AGED; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HUMANS; LIKELIHOOD FUNCTIONS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; RISK FACTORS; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 0033428434     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Yoshino K, Asanuma F, Hanatani Y, et al: Multiple primary cancer in the stomach and another organs: frequency and the effects on prognosis. Jpn J Clin Oncol 15 (Suppl. 1): 183-190, 1985.
2. Hoar SK, Wilson J, Blot WJ et al: Second cancer following cancer of the digestive system in Connecticut, 1935-82. Washington; Natl Cancer Inst Monogr 68: 49-82, 1985.
3. Teppo L, Pukkala E, Saxen E: Multiple cancer. An epidemiologic exercise in Finland. J Natl Cancer Inst 75: 207-217, 1985.
4. Lynge E, Jensen OM, Carstensen B: Second cancer following cancer of the digestive system in Denmark, 1943-80. Washington: Natl Cancer Inst Monogr 68: 277-308, 1985.
5. Lerner HJ. Acute myelogenous leukemia in patients receiving chlorambucil for stage II breast cancer. Cancer treat Rep 62: 1135-1138, 1978.
6. Greene MH, Boice JD, Greer BE, et al: Acute nonlymphocytic leukemia after therapy with alkylating agents for ovarian cancer. A study of five randomized clinical trials. N Eng J Med 307: 1416-1421, 1982.
7. Boice JD, Greene MH, Killen Jr. JY et al: Leukemia and preleukemia after adjuvant treatment of gastrointestinal cancer with semustine (methyl-CCNU). N Eng J Med 309: 1079-1084, 1983.
8. Tucker MA, Coleman CN, Cox RS, et al: Risk of second cancers after treatment for Hodgkin's disease. N Eng J Med 318: 76-81, 1988.
9. Valagussa P, Tancini G, Bonadonna G: Second malignancies after CMF for resectable breast cancer. J Clin Oncol 5: 1138-1142, 1987.
10. Arriagada R, Rutqvist LE: Adjuvant chemotherapy in early breast cancer and incidence of new primary malignancies. Lancet 338: 535-538, 1991.
11. Nakajima T, Takahashi A, Takagi K, et al: Comparison of 5-fluorouracil with ftorafur in adjuvant chemotherapy with combined inductive and maintenance therapies for gastric cancer. J Clin Oncol 2: 1366-1371, 1984.
12. Kim JP: The concept of immunochemosurgery in gastric cancer. World J Surg 11: 465-472, 1987.
13. Nakazato H, Koike A, Saji S, et al: Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. The Lancet 343: 1122-1226, 1994.
14. Blokhina NG, Garin AM, Moroz LV, et al: Treatment with 5- fluorouracil in prophylaxis of relapses and metastases of stomach cancer. Neoplasma 19: 351-356, 1972.
15. Lise M, Nitti D, Marchet A, et al: Final results of a phase III clinical trial of adjuvant chemotherapy with the modified fluorouracil, doxorubicin, and mitomycin regimen in resectable gastric cancer. J Clin Oncol 13: 2757-2763, 1995.
16. Hiyama T, Hanai A, Fujimoto I: Second primary cancer after diagnosis of stomach cancer in Osaka, Japan. Jpn J Cancer Res 82: 762-770, 1991.
17. Kaibara N, Maeta M, Ikeguchi M: Patients with multiple primary gastric cancers tend to develop second primaries in organs other than the stomach. Surg Today (Jpn J Surg) 23: 186-188, 1943.
18. Ichikawa T, Iwanaga T, Taniguchi K, et al: Double malignancies in the stomach and other organs - analysis with the person-years method. J Jpn Soc Cancer Ther 19: 2157-2167, 1984.
19. Kato I, Kito T, Nakazato H, Tominaga S. Second malignancy in stomach cancer patients and its possible risk factors. Jpn J Clin Oncol 16: 373-381, 1986.
20. Caygill CPJ, Hill MT, Hall CN, et al: Increased risk of cancer at multiple sites after gastric surgery for peptic ulcer. Gut 28: 924-928, 1987.
21. Bundred NJ, Whitfield BCS, Prescott RJ, et al: Gastric surgery and the risk of subsequent colorectal cancer. Br J Surg 72: 618-619, 1985.
22. Tominaga K, Koyama Y, Sasagawa M, et al: A follow-up study of resected stomach cancer patients with special emphasis on the incidence of second primary cancers. Jpn J Clin Oncol 23: 331-335, 1993.
23. Furukawa H, Hiratsuka M, Iwanaga T, et al: Treatment for second malignancies after gastrectomy for stomach cancer. Hepato-Gastroenterol 43: 194-198, 1996.
24. Maehara Y, Tomisaki S, Emi Y, et al: Clinicopathological features of patients who died with second primary cancer after curative resection for gastric cancer. Anticancer Res 15: 1049-1054, 1995.
25. Watanabe S: Epidemiology of multiple primary cancer. Jpn J Cancer Chemother 17: 967-973, 1990.
26. Niimoto M, Hirono M, Hattori T, et al: Second malignancies after gastrectomy for gastric cancer. Jpn J Cancer Chemother 13: PART 11: 1475-1483, 1986.
27. Narisawa T, Kohno K, Yamaguchi T, Takahashi T: Chemoprevention of development of colonic adenomatosis and carcinomatosis with intrarectal dose of 5-FU on animal model. Cancer 45: 439-443, 1980.
28. Narisawa T, Sato M, Tani M, Takahashi T: Chemoprevention of development of colonic adenomatosis and carcinomatosis with 5-fluorouracil and ftorafur on animal model. J Cancer Res Clin Oncol 97: 223-232, 1980.
29. Sagara T: The effect of UFT in thymidine kinase and thymidylate synthetase activities and autoradiograph in DMH-induced colon cancer in rat. J Jpn Soc Cancer Ther 22: 1169-1175, 1987.
30. Aida Y, Sunaga T, Maeyama S, et al: Inhibitory effect of UFT on rat hepatocarcinogenesis induced by 3'-methyl-4-dimethyl- amino-azobenzene and phenobarbital promotion. Jpn J Cancer Chemother 18: 2597-2602, 1991.
31. Minaguchi S: A study on the effects of various immunomodulators on ENNG carcinogenesis of rats. KitaKantou Igaku 38: 41-53, 1988.
32. Nakajima T, Ichikawa S, Uchida S, Komada T. Effects of a protein-bound polysaccharide from a basidiomycetes against hepatocarcinogenesis induced by 3'-methyl-4-dimethylamino-azobenzene in rats. Clin Ther 12: 385-392, 1990.
33. Yoshida S: The effect of long term oral administration of 5-fluorouracil and PS-K on the glandular stomach of rats treated with N-methyl-N'-nitro-N-nitrosoguanidine. Tokyo Jikeikai Med J 102: 1625-1636, 1987.